أعرض في EDS

A phase 3 study (COSMIC-313) of cabozantinib in combination with nivolumab and ipilimumab in patients with previously untreated advanced renal cell carcinoma of intermediate or poor risk

التفاصيل البيبلوغرافية
العنوان: A phase 3 study (COSMIC-313) of cabozantinib in combination with nivolumab and ipilimumab in patients with previously untreated advanced renal cell carcinoma of intermediate or poor risk
المؤلفون: F. Wang, Laurence Albiges, T. Powles, N. Mohamed, T. Choueiri, Robert J. Motzer, A. Geng
المصدر: European Urology Open Science, Vol 21, Iss, Pp S188-(2020)
بيانات النشر: Elsevier, 2020.
سنة النشر: 2020
مصطلحات موضوعية: Oncology, medicine.medical_specialty, Poor risk, Cabozantinib, business.industry, Urology, Phases of clinical research, Ipilimumab, medicine.disease, lcsh:Diseases of the genitourinary system. Urology, lcsh:RC870-923, lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens, lcsh:RC254-282, chemistry.chemical_compound, chemistry, Renal cell carcinoma, Internal medicine, medicine, In patient, Nivolumab, business, medicine.drug
اللغة: English
تدمد: 2666-1683
URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1762ae0f58bd9ad364847ce97dfe8ef0
http://www.sciencedirect.com/science/article/pii/S2666168320362352
حقوق: OPEN
رقم الأكسشن: edsair.doi.dedup.....1762ae0f58bd9ad364847ce97dfe8ef0
قاعدة البيانات: OpenAIRE
الوصف
تدمد:26661683